DBV Technologies (EURONEXT: DBV/ NASDAQ: DBVT) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®.

Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT®, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin®.

Currently, we are advancing Viaksin® to treat patients, including infants and children, suffering from severe food allergies.